





RealRate

PHARMACEUTICAL 2020

Paratek Pharmaceuticals Inc. Rank 292 of 358



The relative strengths and weaknesses of Paratek Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Paratek Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 212% points.

The company's Economic Capital Ratio, given in the ranking table, is -73%, being 109% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	243,354
Cost of Goods Sold	3,484
Intangible Assets	829
Liabilities, Current	24,200
Liabilities, Non-Current	266,526
Other Assets	5,669
Other Compr. Net Income	202
Other Expenses	16,735
Other Liabilities	0
Other Net Income	3,574
Other Revenues	16,544
Property and Equipment	1,227
Research and Development	39,554
Selling, General and Administrative Expense	89,135

Output Variable	Value in 1000 USD
Assets	251,079
Liabilities	290,726
Expenses	148,908
Revenues	16,544
Stockholders Equity	-39,647
Net Income	-128,790
Comprehensive Net Income	-128,689
Economic Capital Ratio	-73%